The objective of this study was to evaluate the impact of pre-analytical factors on the short and long term stability of ascorbic acid (AA), the main form of vitamin C in whole blood and plasma. The effects of various anticoagulants, acidification, storage temperature and time were tested. A recently developed fast and sensitive HPLC method was used to measure AA levels. AA baseline values observed in heparin plasma were significantly higher than values observed in EDTA, citrate and Stabilyte plasma, as well as in serum. pH and temperature were identified as additional critical pre-analytical factors during the short, medium and long term handling and storage. Thus, assessment of reliable and accurate AA status in biological samples demonstrates to be highly dependent on whether the initial conditions during sample handling are controlled. In conclusion, heparin tubes should be used for blood sample collection. As AA is rapidly degraded, sample collection should be followed by immediate centrifugation and plasma acidification. To avoid further degradation during sample handling, samples should be stored at À701C without delay and analyzed within 80 days.
Introduction
Vitamin C is present in plasma in two main forms; the reduced form ascorbic acid (AA) and the oxidized form dehydroascorbic acid (DHAA). The ratio between DHAA and AA may serve as an important plasma biomarker of oxidative stress. AA is the most abundant form in plasma and sensitive to oxidation and degradation during blood sampling, handling, storage, and analysis (Washko et al., 1992; Levine et al., 1999) . Various factors such as choice of anticoagulant, temperature, light, pH, dissolved oxygen, solvent, ionic strength, trace metals as ferric ions or the presence of oxidizing enzymes have been reported to affect AA stability (Bradley et al., 1973; Lunec and Blake, 1985; Galan et al., 1988; Margolis and Davis, 1988; Comstock et al., 1995; Key et al., 1996; Margolis and Duewer, 1996; Chung et al., 2001; Ching et al., 2002) . It is essential to avoid degradation and oxidation of AA during sampling, sample handling and analysis, as this may skew the ratio between DHAA and AA. As DHAA is unstable at biological conditions, the ratio between DHAA and AA is usually measured as total AA (TAA) with the use of subtraction methods (Washko et al., 1992; Levine et al., 1999; Lykkesfeldt, 2000) . The stability of TAA and DHAA are not discussed herein, as it is the preservation of AA in its reduced form that is the essential aspect of accurate DHAA and TAA measurements.
To our knowledge, only limited and scattered data have been reported earlier and in general only one of several aspects has been evaluated (Lunec and Blake, 1985; Galan et al., 1988; Margolis and Davis, 1988; Comstock et al., 1995; Key et al., 1996; Margolis and Duewer, 1996; Chung et al., 2001; Ching et al., 2002) . Furthermore, the majority of these studies use supplemented plasma or serum, (Margolis and Davis 1988; Margolis et al., 1990 Margolis et al., , 1991 Margolis and Duewer 1996) , which may not reflect the degradation pattern that is expected in fresh samples.
Our study provides a detailed and systematic elucidation on how pre-analytical factors such as choice of anticoagulant, pH and temperature affect the degradation of AA in freshly drawn whole blood and plasma under conditions that are highly relevant with respect to experimental studies and clinical practice. To our knowledge, the effects of short-term storage (3-6 h) of non-acidified serum or plasma at room temperature, medium-term storage (12 wk) of non-acidified plasma at À201C and long-term storage (2 y) of acidified plasma at À201C have not been previously reported.
Materials and methods
A recently published HPLC method for rapid and accurate determination of AA was used throughout the study. (Karlsen et al., 2005) In short, blood was collected by venous puncture from 4 healthy, adult volunteers using heparin, EDTA, citrate or Stabilyte vacutainer tubes, or vacutainer tubes without anticoagulants (serum). The amount of anticoagulant solution in the different tubes was used for adjustment as the AA concentrations were calculated. The use of human blood for the purpose of method validation does not require ethical permission in Norway. However, all participants signed an informed consent describing the rationale behind the study, allowing their blood samples to be used for this purpose.
Whole blood was centrifuged (2,000 g) at þ 41C for 10 min for generation of plasma. Plasma was immediately acidified using an equal volume of 10% meta-phoshoric acid (MPA). The MPA solution that was used throughout the study was freshly prepared (e.g. within 14 days and stored at þ 41C). The acidified samples were centrifuged (3,000 g) at 41C for 15 min. For preparation of serum, vacutainers without anticoagulants were stored for 15 min before centrifugation and acidification. The clear supernatant was then diluted 5 times in the mobile phase in an autosampler vial and thoroughly mixed before 5 mL was used for chromatographic analysis. The mobile phase consisted of 2% acetonitrile in 2.5 mmol/L NaH 2 PO 4 , 2.5 mmol/L dodecyltrimethyl ammonium chloride and 1.25 mmol/L Na 2 EDTA in milli-q water. The flow rate was 6.0 mL/min. For separation of AA from interfering plasma constituents, a Chromolith Performance RP18-e, 4.6 Â 100 mm column was used. A variable wavelength UV detector was used at 264 nm.
To evaluate the degree of degradation of AA after blood collection but prior to plasma generation, whole blood were left at room temperature and analyzed at various time intervals. Furthermore, the stability of AA was studied in acidified and non-acidified plasma during short-term storage at room temperature and þ 41C and during long-term storage at À201C and À701C.
Results are reported as median values (s.d.). Statistical analysis was performed using ANOVA in SPSS version 13.0.
Results and discussion
Significant differences in baseline AA level in serum and plasma containing different anticoagulants were observed (Figure 1 ). The highest AA levels were observed in heparin and EDTA plasma and serum. A non-significant degradation of 2.8% (s.d. ¼ 0.3%, P ¼ 0.829) and 5.6% (s.d. ¼ 2.0%, P ¼ 0.513) were observed in EDTA plasma and serum, respectively, as compared to heparin plasma. The levels in citrate and Stabilyte plasma were significantly lower compared to heparin plasma: A 7.8% (s.d. ¼ 2.3%, P ¼ 0.020) and 22.7% (s.d. ¼ 2.1%, P ¼ 0.001) decline was observed in citrate and Stabilyte plasma, respectively. When whole blood was stored at room temperature before the preparation of plasma or serum a rapid degradation of AA was observed in all tubes (Figure 1 ). Heparin plasma was most stable with only about 5 % degradation the first 3 h.
In a few studies data on initial values of AA in different vacutainer tubes have been reported (Ching et al., 2002; Rumelin et al., 2003) . Our observation, which is in accordance with these earlier more limited studies, demonstrates that AA is most stable in plasma isolated from heparin tubes.
The time at room temperature before the initial centrifugation of whole blood vary from study to study, and most likely also in clinical practice. With respect to degradation of AA in whole blood stored at room temperature before plasma or serum preparation only scattered data have been reported (Liau et al., 1993; Ching et al., 2002; Rumelin et al., 2003; Terzuoli et al., 2004) . Our data suggest that stability is preserved best in heparin and citrate vacutainer tubes. Additionally, as the initial levels of AA were significantly degraded in citrate tubes, the use of heparin tubes is an obvious choice for AA determination in human blood.
We then tested the effects of acidification and temperature on storage of heparin plasma before AA analysis (Figure 2) . Our results demonstrates that acidification dramatically Stability of AA in whole blood and plasma A Karlsen et al reduce AA degradation both at room temperature and at 41C. Furthermore, much less degradation occurred at 41C compared to room temperature. Whereas only 0.9% (s.d. ¼ 0.5%) degradation was observed in acidified samples stored at 41C for 2 h, a non-significant decline of 5.6% (s.d. ¼ 3.9%) was observed in non-acidified plasma (P ¼ 0.164). Significant degradation in acidified and non-acidified plasma at room temperature was observed at the same time interval, a 5.9% (s.d. ¼ 4.3%, P ¼ 0.049) and 10.8% (s.d. ¼ 4.9%, P ¼ 0.001) degradation were observed, respectively. Similar results were observed when whole blood was stored at the same conditions (data not shown). Previously reported data on AA stability in plasma are scarce, and due to differences in experimental design, the limited data may not easily be compared (Lykkesfeldt et al., 1995; Ching et al., 2002) . Our study provides a full elucidation on the degradation of AA in plasma and whole blood under conditions that are highly relevant with respect to experimental studies and clinical practice.
Long-term storage of plasma demonstrated that pH and temperature are important also during storage and freezing; AA in acidified heparin plasma is fairly stable when stored at À701C as no degradation is observed until approximately 80 days of storage. After this time interval a 6.8% (s.d. ¼ 5.7%) decline is observed during the first year, and after two years of storage 14% (s.d. ¼ 3.8%) of the AA is lost. This is a more extensive loss then that reported by others.
The AA degradation pattern in non-acidified samples at À701C and acidified samples at À201C were similar; no degradation was observed until day 20, followed by a significant decline. In non-acidified plasma stored at À201C no AA was detected after 3 months (data not shown). The data on degradation during storage at À701C are in accordance to that previously reported (Comstock et al., 1995; Margolis and Duewer, 1996) . However, for storage at À201C, only limited data are reported (Nagy and Degrell, 1989; Lykkesfeldt et al., 1995; Esteve et al., 1997) .
Margolis et al. have previously investigated several aspects of AA stability in human blood samples (Margolis and Davis 1988; Margolis et al., 1990 Margolis et al., , 1991 Margolis and Duewer 1996) . However, these studies have used AA-depleted serum (e.g. naturally degraded during storage), supplemented with AA. Additionally, dithiothreitol have been used for preservation and AA is usually measured as total AA. We hypothesize that the degradation pattern of total AA as compared to AA and in depleted plasma as compared to fresh plasma may not easily be compared.
Conclusion
In this study, the influence of critical pre-analytical factors such as choice of anticoagulant, pH and temperature on AA stability have been thoroughly investigated. We observed that heparin vacutainer tubes were preferable for blood sample collection. As AA is rapidly degraded in whole blood and plasma, sample collection should be followed by immediate centrifugation and plasma acidification. To avoid degradation during sample handling, samples should immediately be stored at À701C without delay, and analyzed within 80 days. If plasma samples are not acidified, analysis must be performed within 14 days when stored at À701C. Samples stored at À201C should not be used for AA analysis, as substantial degradation of AA are observed after only one day of storage. A chromatographic method should be used, as the enzymatic or spectrophotometric assays have been associated with substantial interferences in several reviews on vitamin C methodology (Pachla et al., 1985; Washko et al., 1992; Levine et al., 1999) . It is also preferable that the method provides a high throughput of samples, as the stability of AA is limited in prepared samples (Karlsen et al., 2005) .
We observed that conditions commonly used in clinical practice (e.g. delays between sampling and further handling) may result in significant degradation of AA in plasma. As accurate determination of AA in its native form is essential, it is important to minimize the degradation and oxidation during sampling, sample handling and analysis. It would be beneficial if pre-analytical and analytical procedures for determination of AA are standardized to control critical factors in future experimental studies as well as in clinical practice. Stability of AA in whole blood and plasma A Karlsen et al
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